

Are you interested in supporting research into chronic spontaneous urticaria (CSU)?

This information is about a research study for people with CSU. Your healthcare provider has shared this information with you because they think the study might be suitable for you.



Please take your time to read this information.

You can ask your healthcare provider any questions you have about this study.



Joining this study is voluntary and optional.

If you decide not to take part, you do not need to give a reason.



The title of this study is 'Remibrutinib in real-world clinical practice: a prospective, multi-country, non-interventional, effectiveness and safety study (REASSERT).'

What is the REASSERT study?

This study is for people with CSU who are having treatment with:

- an antihistamine,
- a medicine called remibrutinib, or
- both of these treatments.

The **REASSERT study** will ask you questions about how your treatment affects you. This will help researchers understand:

- how well prescribed treatments work over time to relieve your symptoms,
- if, or when, a stronger treatment needs to be prescribed to manage your symptoms, and
- how these treatments impact your quality of life.

Why is this study taking place?

CSU can be unpredictable. It affects people physically, emotionally, and socially. As there is no known cause, it is important that treatments help to manage symptoms while supporting people's quality of life.

The **REASSERT study** includes people being cared for in specialist centers as well as in local healthcare systems (such as with an allergist, immunologist, dermatologist, or general practitioner). This helps us to understand how people across the globe are being treated.



Over 3000 people from 8 countries

will take part in this global study.



No additional treatment or tests

will be needed as part of this study. You will continue your treatment and care plan as decided by you and your doctor.



You could help us learn more about treating CSU.

This can improve how CSU is managed in the future, and how people with CSU are supported.

What will happen during the study?

Over 2 years, you will share your experiences through a phone app and during regular visits to the study doctor. Your healthcare provider can share more information about these activities.



In the first 3 months of the study, you will:

- visit the study doctor as per your usual care plan,
- complete a daily or weekly diary about your medicine and symptoms, and
- complete surveys about your daily life.

Between 3 months and 2 years of the study, you will:

- visit the study doctor up to 7 times as per your usual care plan,
- complete a weekly diary about your medicine and symptoms, and
- complete surveys about your daily life.



Collecting information

As CSU symptoms can come and go, this study is collecting information from people even if they do not have symptoms or are not taking any medicine at that time.



Surveys about your daily life

Surveys about how CSU affects you will ask about your sleep, your ability to work or do other tasks, and your emotional wellbeing. Your responses help researchers understand how CSU impacts people and how treatment can help.



You will be compensated for your time completing the surveys.



Your responses and information are kept private, and can only be seen by authorized study staff.



After the study is complete, your study doctor can share information about the overall study results with you.



This study aims to answer questions about the way CSU is being treated.

By taking part in this study, you could help to improve the way people with CSU across the globe are being cared for. If you are interested in this study and think you could take part for the full 2 years, please speak to your healthcare provider.